HHS' Azar Defends Value Of "Me Too" Drugs
This article was originally published in The Pink Sheet Daily
Government market controls stifle innovation and patient access to care, HHS deputy secretary says.
You may also be interested in...
Deputy Sectary to leave after five and a half years with department; no successor announced.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.